Cord blood is increasingly used as an alternative stem cell source for
autologous and allogeneic transplantation, particularly in pediatric
patients, We therefore adopted our protocol for transplanting human ad
ult bone marrow cells into severe combined immunodeficient (SCID) mice
[1] to develop an in vivo model for cord blood hematopoiesis. Intrave
nous injection of unfractionated or Ficoll-separated cord blood cells
into sublethally irradiated SCID mice led to high levels of human hema
topoiesis in the majority of the recipients [2]. Multilineage human he
matopoiesis including committed and multipotential myeloerythroid prog
enitors as well as CD19(+) B-lymphoid cells were observed in the murin
e bone marrow for at least 18 weeks, Together, these data indicate tha
t the SCID mice were engrafted with an immature cell that was able to
maintain multiple progenitor lineages in vivo. In contrast to our expe
riences with adult bone marrow, high levels of human cell engraftment
in the mouse could be achieved without exogenous cytokine treatment, s
uggesting that the cord blood cells respond differently to the murine
microenvironment, Alternatively, the cord blood cells might have been
able to provide themselves with the necessary growth factors in a para
crine fashion. This model will be useful in gaining new insights into
the biology of immature human cord blood progenitors and cord blood tr
ansplantation.